1565363922     

495363928                        

---

Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma / M. Thiemann, C. Gieffers, C. Kunz, J. Sykora, C. Merz, H. Fricke, B. Wiestler, W. Wick

Thiemann, Markus [Verfasserin/Verfasser]

Wiestler, Benedikt, 1983- [Verfasserin/Verfasser] ; Wick, Wolfgang, 1970- [Verfasserin/Verfasser]

Annals of oncology : official journal of the European Society for Medical Oncology . - Amsterdam [u.a.] : Elsevier ; Dordrecht [u.a.] : Kluwer, 1990-. - 27(2016,Supplement 6) Artikel-Nummer 133P, 1 Seite

Englisch

Gesehen am 15.11.2017

Elektronische Ressource: Zugang beim Produzenten (Lizenzangabe: Kostenfrei zugänglich ohne Registrierung)

Elektronische Ressource: Zugang beim Produzenten (Lizenzangabe: Kostenfrei zugänglich ohne Registrierung)

Digital Object Identifier (DOI): 10.1093/annonc/mdw363.81

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: APG101, a fully human fusion protein consisting of the extracellular domain of CD95 and the Fc-domain of an IgG, has been developed by Apogenix. It was confirmed as a potent inhibitor of CD95L induced invasion of glioblastoma cells in vitro. In a randomized phase 2 study in glioblastoma patients with 1st or 2nd relapse the combined therapy of APG101 plus radiotherapy (RT) was found to be superior to RT alone in a clinically relevant order of magnitude in all efficacy endpoints (i.e. PFS-6, PFS and OS). At the same time APG101 exhibited an excellent safety profile and was well tolerated. The presented data summarizes the identification of a predictive biomarker.Methods: To identify potential biomarkers we used available tissue sections originating...